Stability of rifampin in plasma: Consequences for therapeutic monitoring and pharmacokinetic studies

Therapeutic Drug Monitoring

Volumn 19, Issue 6, 1997, Pages 669-674

  Le Guellec, Chantal ^a   Gaudet, Marie Laure ^a   Lamanetre, Sandrine ^a   Breteau, Michel ^a  

^a CHU BRETONNEAU   (France)

Author keywords

Drug monitoring; Pharmacokinetics; Plasma; Rifampin; Stability

Indexed keywords

RIFAMPICIN;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CHEMOPROPHYLAXIS; DEGRADATION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL;

ANTIBIOTICS, ANTITUBERCULAR; ASCORBIC ACID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG STABILITY; HUMANS; RIFAMPIN; TEMPERATURE;

EID: 0031469680     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199712000-00011     Document Type: Article

References (13)

1. Mandell GL, Sande MA. Antimicrobial agents. In: Gilmans A, Goodman LS, Rall TW, et al., eds. The pharmacological basis of therapeutics. New York: Macmillan, 1985:1199-218.
2. Acoccella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27.
3. Acoccella G, Pagani V, Marchetti M, et al. Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy 1971;16:356-70.
4. Lecaillon JB, Febvre N, Metayer JP, et al. Quantitative assay of rifampicin and three of its metabolites in human plasma, urine and saliva by high-performance liquid chromatography. J Chromatrogr 1978;145:319-24.
5. Guillaumont M, Leclerc M, Frobert Y, et al. Determination of rifampicin, deacetylrifampicin, isoniazid and acetylisoniazid by high-performance liquid chromatography: application to human serum extracts, polymorphonucleocytes and alveolar macrophages. J Chromatogr 1982;232:369-76.
6. Ratti B, Rosina Parenti R, Toselli A, et al. Quantitative assay of rifampicin and its main metabolite 25-deacetylrifampicin in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr 1981;225:526-31.
7. Woo J, Wong CL, Teoh R, et al. Liquid Chromatographic assay for the simultaneous determination of pyrazinamide and rifampicin in serum samples from patients with tuberculous meningitis. J Chromatogr 1987;420:73-80.
8. Jamaluddin AB, Sarwar G, Rahim MA, et al. High-performance liquid Chromatographic assay of rifampicin in human serum. J Chromatogr 1990;525:495-7.
9. El-Yazigi A, Raines DA. Simultaneous microdetermination of rifampin, deacetylrifampin, isoniazid, and acetylisoniazid in plasma by liquid chromatography with dual electrochemical and spectrophotometric detection. Pharm Res 1992;6:812-6.
10. Pearson SD, Trissel LA. Stability and compatibility of minocycline hydrochloride and rifampin in intravenous solutions at various temperatures. Am J Hosp Pharm 1993;50:698-702.
11. Weber A, Opheim KE, Smith AL, et al. High pressure liquid Chromatographic quantitation of rifampin and its two major metabolites in urine and serum. Rev infect Dis 1983;5:S433-9,
12. Koup JR, Williams Warren J, Viswanathan CT, et al. Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther Drug Monit 1986;8:17-22.
13. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability bioequivalence and pharmacokinetic studies. J Pharm Sci 1992;81:309-12.